FDA clears IND for Cerveau’s tau imaging agent

Cerveau Technologies said today that the FDA cleared the investigational new drug application for its tau imaging agent.

The company plans to work with pharmaceutical partners to evaluate the product’s use in positron emission tomography scans to assess neurofibrillary tangles in the brain. NFTs composed of aggregated tau protein are characteristic of certain neurodegenerative conditions like Alzheimer’s disease.

Get the full story at our sister site, Drug Delivery Business News.

The post FDA clears IND for Cerveau’s tau imaging agent appeared first on MassDevice.

from MassDevice http://ift.tt/2sBrItw